SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Operating Lease Cost
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Operating Lease Cost of $22.95 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating lease, cost for the quarter ending 2026-06-30 was $22.95K, a 0.00% change year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating lease, cost for the quarter ending 2026-03-31 was $22.95K, a 0.00% change year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating lease, cost for the quarter ending 2025-12-31 was $22.95K, a 0.00% change year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating lease, cost for the quarter ending 2025-09-30 was $22.95K, a 0.00% change year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating lease, cost for fiscal 2025 was $91.79K, a 0.00% change from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating lease, cost for fiscal 2024 was $91.79K, a 18.06% decline from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating lease, cost for fiscal 2023 was $112.02K, a 59.63% increase from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. operating lease, cost for fiscal 2022 was $70.17K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.95K 10-Q · filed 2026-09-24 | $45.89K 10-Q · filed 2026-09-24 | $68.84K derived: sum of 3 quarters · filed 2026-09-24 | $91.79K derived: sum of 4 quarters · filed 2026-09-24 |
| 2026-03-31 | $22.95K 10-Q · filed 2026-05-15 | $45.89K derived: sum of 2 quarters · filed 2026-05-15 | $68.84K derived: sum of 3 quarters · filed 2026-05-15 | $91.79K derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-12-31 | $22.95K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $45.89K derived: sum of 2 quarters · filed 2026-03-31 | $68.84K derived: sum of 3 quarters · filed 2026-09-24 | $91.79K 10-K · filed 2026-03-31 |
| 2025-09-30 | $22.95K 10-Q · filed 2025-11-13 | $45.89K derived: sum of 2 quarters · filed 2026-09-24 | $68.84K 10-Q · filed 2025-11-13 | $91.79K derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-06-30 | $22.95K 10-Q · filed 2026-09-24 | $45.89K 10-Q · filed 2026-09-24 | $68.84K derived: sum of 3 quarters · filed 2026-09-24 | $91.79K derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-03-31 | $22.95K 10-Q · filed 2026-05-15 | $45.89K derived: sum of 2 quarters · filed 2026-05-15 | $68.84K derived: sum of 3 quarters · filed 2026-05-15 | $91.79K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $22.95K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $45.89K derived: sum of 2 quarters · filed 2026-03-31 | $68.84K derived: sum of 3 quarters · filed 2026-03-31 | $91.79K 10-K · filed 2026-03-31 |
| 2024-09-30 | $22.95K 10-Q · filed 2025-11-13 | $45.89K derived: sum of 2 quarters · filed 2025-11-13 | $68.84K 10-Q · filed 2025-11-13 | $97.63K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $22.95K 10-Q · filed 2025-08-13 | $45.89K 10-Q · filed 2025-08-13 | $74.69K derived: sum of 3 quarters · filed 2025-08-13 | $115.18K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $22.95K 10-Q · filed 2025-05-08 | $51.74K derived: sum of 2 quarters · filed 2025-05-08 | $92.23K derived: sum of 3 quarters · filed 2025-05-08 | $117.42K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $28.79K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $69.28K derived: sum of 2 quarters · filed 2025-02-26 | $94.48K derived: sum of 3 quarters · filed 2025-02-26 | $112.02K 10-K · filed 2025-02-26 |
| 2023-09-30 | $40.49K 10-Q · filed 2024-11-13 | $65.68K derived: sum of 2 quarters · filed 2024-11-13 | $83.23K 10-Q · filed 2024-11-13 | $100.77K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $25.19K 10-Q · filed 2024-09-04 | $42.74K 10-Q · filed 2024-09-04 | $60.28K derived: sum of 3 quarters · filed 2024-09-04 | $77.82K derived: sum of 4 quarters · filed 2024-09-04 |
| 2023-03-31 | $17.54K 10-Q/A · filed 2024-09-04 | $35.09K derived: sum of 2 quarters · filed 2024-09-04 | $52.63K derived: sum of 3 quarters · filed 2024-09-04 | $70.17K derived: sum of 4 quarters · filed 2024-09-04 |
| 2022-12-31 | $17.54K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | $35.09K derived: sum of 2 quarters · filed 2024-09-04 | $52.63K derived: sum of 3 quarters · filed 2024-09-04 | $70.17K 10-K/A · filed 2024-09-04 |
| 2022-09-30 | $17.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $35.09K derived: sum of 2 quarters · filed 2023-11-13 | $52.63K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $17.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $35.09K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $17.54K 10-Q · filed 2023-05-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |